PARP1 and prostate cancer: PARP1, NQO1, HSPA5, and TOP1 were identified as potential molecular targets for ETV4-fusion-positive prostate cancer, and olaparib, amrubicin, fluorouracil, and irinotecan were suggested as candidate drugs, respectively (Table 2).